BMC Cancer

Advances in pre-clinical cancer models

Guest Edited by Ryan C. Fields and Anna Golebiewska

Extracellular vesicles in cancer progression

Guest Edited by: Orazio Fortunato, Irina Matei and Chunlin Ou

Effects of urinary extracellular vesicles from prostate cancer patients on the transcriptomes of cancer-associated and normal fibroblasts

This article studies the effects of urinary EVs from PC patients and healthy males on the transcriptional landscape of prostate CAFs and normal foreskin fibroblasts.

Overall survival in patients with re-excision of positive microscopic margins of limb and trunk wall soft tissue sarcoma operated outside of a reference center: a nationwide cohort analysis

This study aims to explore the impact of systematic re-excision (RE) as adjuvant care on overall survival (OS), local recurrence free survival (LRFS), and local and distant control (RFS) in patients with soft tissue sarcoma (STS).

Sentinel lymph node mapping with superparamagnetic iron oxide for melanoma: a pilot study in healthy participants to establish an optimal MRI workflow protocol

This study shows the potential use of superparamagnetic iron oxide (SPIO) and pre-operative MRI in melanoma patients to identify SLNs. 

BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions in broad areas of cancer research including molecular and cellular biology, genetics, epidemiology, and clinical trials. Learn more about our scope here. 

Pancreatic cancer accounts for about 3% of all cancers in the US and is projected to become the second leading cause of cancer-related death by 2030. 

On occasion of the Pancreatic Cancer Awareness Month we hope you will enjoy reading one of the newest study protocol published in BMC Cancer in 2022 aiming to enhance  chemosensitivity and drug distribution in pancreatic cancer through CAF conversion in the stroma.

Safety and efficacy of MIKE-1 in patients with advanced pancreatic cancer: a study protocol for an open-label phase I/II investigator-initiated clinical trial based on a drug repositioning approach that              reprograms the tumour stroma

Interested in joining the editorial board of BMC Cancer?

More information and how to apply can be found here. We are looking forward to hearing from you.